
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics demonstrates a solid financial foundation through its innovative use of the proprietary PREDATOR platform, which positions the company to advance its unique INDUKINE therapies targeting the tumor microenvironment. The adjustment to Core FFO guidance, reflecting a midpoint increase of $0.03, indicates the company's ability to navigate costs effectively while still achieving growth. Additionally, the impressive metrics of 4.3% blended rent growth and 4.1% same-store NOI expansion showcase a thriving operational landscape, enhancing investor confidence in the company's future prospects.
Bears say
Werewolf Therapeutics Inc. faces a negative outlook due to lowered growth expectations reflected in its financial metrics. The company's performance indicators suggest a decline in revenue, alongside a 3.8% year-over-year rise in expenses, resulting in a 2.6% decline in net operating income (NOI). Additionally, average effective rental rates have decreased by 50 basis points year-over-year, attributed to a significant decline in new lease rates, indicating challenges in achieving desired growth against the backdrop of market supply conditions.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares